logo-loader
viewOrthocell Ltd

Orthocell rises on reporting 87.5% success rate for Ortho-ATI® cell therapy treatment of chronic tendon injuries

The study captures patient feedback/outcomes for reduction of pain, functional improvement and overall satisfaction, in patients suffering from chronic tendon injuries

Orthocell Ltd - Orthocell reports 87.5% success rate for Ortho-ATI® cell therapy treatment of chronic tendon injuries
The study results correlate to clinical study outcomes published in leading scientific journals

Orthocell Ltd (ASX:OCC) is higher after releasing results from its 2019 Annual Quality Study, which show an 87.5% patient satisfaction rating using Ortho-ATI® cell therapy for the treatment of chronic tendon injuries of the shoulder and a 74.3% patient satisfaction rating in all patient groups including, elbow, hip, knee and ankle.

The company administers the study to capture patient feedback following treatment of chronic tendon injuries with Orthocell’s Ortho-ATI® cellular therapy.

It indicated that 87.5% of shoulder patients were satisfied with how Ortho-ATI® relieved symptoms (ie chronic pain) and improved ability to perform everyday activities at home and at work.

Further evidence

Managing director Paul Anderson said: “The 2019 Annual Quality Study has provided further evidence that Ortho-ATI® is a breakthrough technology that significantly improves patients’ lives returning them to normal function at home and at work, pain-free.

“This is important real-world evidence that adds to our growing body of supporting data.”

Shares have been as much as 16% higher to 39.5 cents.

The company considers the annual study an important measure of patient satisfaction with the Ortho-ATI® cell therapy which also compliments Orthocell’s formal clinical studies that have been published in leading scientific journals, including the American Journal of Sports Medicine, reporting similar positive outcomes.

Ortho-ATI® treatment sites for 2019 Annual Quality Study

Annual quality study results

Orthocell has conducted the annual quality study four times since 2015, receiving 161 responses in total.

Thirty-nine patients responded to the 2019 study, including 21 females and 18 males with a mean age of 52.

A 74.3% satisfaction rate was reported in patients who received Ortho-ATI® tendon repair treatment in the four AQS surveys conducted between 2015 and 2019.

Patient case studies

Of particular interest to new and long-term supporters are the patient case studies Orthocell is now starting to capture, particularly those that show the strong performance of Ortho-ATI® therapy, over a long period of time.

One of these stories relates to well-known AFL star, Daniel Kerr, who played 220 games for the West Coast Eagles between 2001 and 2013.

At the age of 28, he suffered a complete hamstring rupture, which doctor’s described as a “career-ending injury” but after exhausting traditional surgical and non-surgical treatments, he finally found Ortho-ATI®.

His story is detailed in the following video:

Daniel’s experience shows the suitability of this therapy at the highest echelons of professional sport – and Orthocell's previous and ongoing research shows that Ortho-ATI® has a broad reach and appeal for other patient cohorts.

Quick facts: Orthocell Ltd

Price: 0.34 AUD

ASX:OCC
Market: ASX
Market Cap: $62.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orthocell preparing for launch in the US for its CelGro® bone regeneration...

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott following the news they've completed a submission to the US Food and Drug Administration (FDA) seeking 510(k) clearance for marketing its CelGro® product for dental guided bone and soft tissue regeneration...

on 26/5/20

3 min read